Technology License Agreements and Liability Restructuring (Details Narrative) - USD ($)	1 Months Ended				9 Months Ended	12 Months Ended
	Jan. 31, 2020	Nov. 30, 2019	Oct. 31, 2019	Oct. 31, 2005	Sep. 30, 2020	Dec. 31, 2019
Contingency payments, description					The Company has not reflected the contingent amounts payable of $397,449 in the Consolidated Balance Sheet as the payable is contingent on FDA approval and commercialization of the product.
Accrued salaries					$ 2,986,717
Technology License Agreements [Member]
Contingency payments, description				The Company completed a transaction with Schering AG Group, Germany (now part of Bayer AG) and related licensors, to certain patents covering (1) methods of gene therapy from the Regents of University of California (the (UC License Agreement); and (2) the DNA sequence for Fibroblast Growth Factor - 4 (FGF-4) from New York University (NYU License Agreement), for the transfer or license of certain assets and technology for potential use in treating ischemic and other cardiovascular conditions. Under the terms of the transaction, the Company paid Schering a $4 million fee, and would be required to pay a $10 million milestone payment upon the first commercial sale of each resulting product. The Company also may be obligated to pay the following future royalties to Schering: (i) 5% on net sales of an FGF-4 based product such as Generx, or (ii) 4% on net sales of other products developed based on technology transferred to Gene Biotherapeutics by Schering. The royalty rate is reduced to 2% on net sales for an FGF-4 based product following the expiration of the issued patients on a country-by-country basis. As of December 31, 2019, all such worldwide patients have expired.
UC License Agreements [Member]
Unpaid fees, outstanding			$ 1,006,709
Litigation settlement, amount			172,449
Contingency accrual, payments			100,000
Cash payments, quarterly			8,333
Additional lumpsum payment, payable			$ 72,449
NYC License Agreements [Member]
Litigation settlement, amount		$ 400,000
Litigation settlement payable, description		(1) $75,000 in six quarterly payments of $12,500 commencing June 15, 2020, with additional contingent payments due as follows (2) $100,000 payable upon FDA approval to market and sell Generx; and (3) an additional amount totaling $225,000 when commercial US sales cumulatively reach $100 million for Generx.
U.S. Food and Drug Administration [Member]
Contingency payments, description						The total liabilities payable by the Company in the event of FDA approval is $172,449 and an additional amount totaling $225,000 is payable when commercial sales cumulatively reach $100 million for Generx.
Contingency accrual, payments						$ 172,449
Liability restucturing, description	(a) the FDA's approval of Generx for marketing and sale in the U.S.; (b) the EMA approval of Generx for marketing and sale in the European Union and the United Kingdom; (c) the sale of Generx to an independent third party for an aggregate value equal to or greater than $35,000,000; (d) our entry into a strategic partnership that would facilitate a capital contribution equal to or greater than $35,000,000 for the purpose of supporting the clinical and commercial development of Generx; (e) our successful completion of a public or private equity offering for the issuance of its common stock equal to $35,000,000; or (f) at such other time, as our board of directors determines that we have the financial ability to make such payments without jeopardizing our ability to operate as a going concern